Pulmonary Fibrosis Biomarker Market Size, Share, Opportunities, And Trends By Test Type (Blood Tests, Imaging Test, Lungs Biopsy), By Indication (Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD), Drug-induced Pulmonary Fibrosis, COVID-19-related Pulmonary Fibrosis, Pneumoconiosis, Sarcoidosis, Others), By End-User (Diagnostic Laboratories, Academic And Research Institutes, Hospital Laboratories, Biopharmaceutical Companies, Others), And By Geography - Forecasts From 2024 To 2029

The pulmonary fibrosis biomarker market is anticipated to show steady growth during the forecast period.

Pulmonary fibrosis is a medical condition characterized by the formation of scar tissue in the lungs, known as fibrosis, leading to respiratory difficulties. The thickening and stiffening of lung tissues caused by scarring hinder the absorption of oxygen into the bloodstream, resulting in breathing challenges. The most common ways to detect or diagnose pulmonary fibrosis are image tests, blood tests, lung biopsy and computer tomography for higher-resolution films of the chest. At present, there are two medications authorized by the Food and Drug Administration (FDA) for managing idiopathic pulmonary fibrosis (IPF). The drugs are nintedanib (Ofev®) and pirfenidone (Esbriet®). Referred to as anti-fibrotic agents, as they have demonstrated in clinical studies their ability to decelerate the progression of fibrosis or scarring in the lungs. These treatments are sanctioned for individuals with mild, moderate, and severe IPF. Drug approvals and new therapies, investment in development of medications, and recent research developments are the driving the pulmonary fibrosis biomarker market growth.

Market drivers:

• Drug approvals and the introduction of new therapies enhance the pulmonary fibrosis market growth.

The field of pulmonary fibrosis treatment is presently witnessing an increase in novel strategies and research. While existing treatments provide only minimal relief, these fresh therapies offer a ray of hope for a future where patients could potentially experience a significant improvement in their quality of life. For instance, according to National center of Biotechnology Information research report in December 2023 Pirfenidone and nintedanib are effective in decelerating the advancement of idiopathic pulmonary fibrosis (IPF). The analysis delves into the potential of new drugs currently in the development stage, providing a glimpse of optimism for the future.

A variety of drug candidates are being tested in clinical trials, each targeting various facets of the disease, which could result in more precise and efficient therapies. Initial findings indicate that these medications have the potential to enhance lung function, slow down disease progression, and enhance the quality of life for patients. Nevertheless, obstacles such as possible side effects and regulatory challenges continue to exist. Bristol Myers Squibb proclaims that BMS-986278, an oral antagonist of lysophosphatidic acid receptor 1 (LPA1), has received breakthrough therapy designation from the U.S. FDA for the management of progressive pulmonary fibrosis (PPF). The recognition represents a noteworthy achievement in the fight against the incapacitating disease.

• Investment in the development of medications propels the pulmonary fibrosis biomarker market growth.

The healthcare market is propelled by the infusion of new drug investments, which in turn leads to the development of fresh treatment alternatives and encourages innovation in associated domains. For instance, in September 2023 Avalyn, a biopharmaceutical company in the clinical stage, has declared the completion of a Series C financing round totaling of $175 million. The company intends to utilize the funds to further progress its inhalation therapies for life-threatening pulmonary diseases, specifically interstitial lung disease. Additionally, Avalyn plans to advance its key clinical assets, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), into mid-stage clinical trials, aiming to enhance upon existing approved medications.

• Recent research developments propel the pulmonary fibrosis biomarker market growth.

Enhancing understanding of the disease to establish a solid foundation for accurate therapies and personalized healthcare, furthermore, driving the market expansion. According to a research study published in the National Center of Biotechnology Information in September 2023, researchers are making advancements in comprehending the involvement of genes in idiopathic pulmonary fibrosis. They have discovered that both common variations and rare mutations in different genes play a part in the susceptibility to the development and progression of the disease. The most significant association is with a variant in the MUC5B gene, although its effects on disease advancement and survival remain uncertain.  

Furthermore, recent discoveries indicate shared genetic connections between Idiopathic Pulmonary Fibrosis and other fibrotic lung conditions, suggesting common underlying mechanisms. Although the specific functions of individual genes are still being deciphered, these breakthroughs provide valuable insights into the complexities of IPF and hold promise for future enhancements in diagnosis, treatment, and, ultimately, patient outcomes.

North America is expected to grow significantly.

North America is projected to account for a significant share of the pulmonary fibrosis biomarker market due to the increasing number of initiatives in the region. Key initiatives in the battle against pulmonary fibrosis involve enhancing awareness and enhancing the availability of care. According to Canadian Pulmonary Fibrosis Foundation September 2023 in Canada was dedicated to raising awareness about Pulmonary Fibrosis. Canadian Pulmonary Fibrosis Foundation (CPFF) organized several initiatives to achieve the goal, which included an advertising campaign emphasizing the consequences of late diagnosis of PF, informative webinars, and community walks held throughout the country.

The American Lung Association’s “Public Policy and Advocacy Program (2023-2024)” priorities included enhancing financial support for the research, prevention, diagnosis, interventions, treatment, and solutions for various lung conditions such as asthma, COPD, COVID-19, influenza, lung cancer, pulmonary fibrosis, and tuberculosis.

Market Restraints:

• Diversity of the illness curbs the pulmonary fibrosis biomarker market growth.

Pulmonary fibrosis consists of several subtypes with distinct causes and progression of the disease. It is essential to develop biomarkers tailored to each subtype, although this necessitates a deeper comprehension of the complexity of the disease.

Key Developments:

• In May 2022: Sandoz introduced the initial generic pirfenidone in the United States to assist patients with idiopathic pulmonary fibrosis, expanding its range of respiratory drugs. Pirfenidone is indicated for the management of IPF, a progressive disease marked by irreversible lung scarring and breathing challenges.

Company products:

• The Envisia Genomic Classifier (EGC):  offered by Veracyte is a diagnostic tool utilized for identifying interstitial lung disease (ILD). The tissue-based assay employs an algorithmic analysis test to provide accurate results. A genomic pattern of the usual interstitial is identified by the test through the utilization of robust RNA sequencing and machine-learning technology.
• Esbriet (pirfenidone): Esbriet (pirfenidone) offered by Genentech (Roche) is a prescribed drug that is utilized for the treatment of IPF, a persistent lung condition that results in scarring and rigidity in the lungs, thereby causing breathing difficulties.

Segmentation

• By Test Type
  • Blood Tests
  • Imaging Test
  • Lungs Biopsy
• By Indication
  • Idiopathic pulmonary fibrosis (IPF)
  • Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)
  • Drug-induced pulmonary fibrosis
  • COVID-19-related pulmonary fibrosis
  • Pneumoconiosis
  • Sarcoidosis
  • Others
• By End-User
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Hospital Laboratories
  • Biopharmaceutical Companies
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others